RxDoctor Payments Data

Kendell Coburn, DO

Internal Medicine · Ogden, UTNPI 1902365216

Payments from drug & device makers

$4,374in general payments, 2019–2025

Across 240 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$422
  • AbbVie$331
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$284
  • Astellas Pharma US Inc$266
  • Lilly USA, LLC$237
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$4,374100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,374 in reported general payments places this provider in the 85th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$89,818
Medicare patients
148
Services billed
1,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin48$59,967
OzempicSemaglutide50$55,241
EliquisApixaban39$47,684
XareltoRivaroxaban25$35,850
MyrbetriqMirabegron56$35,752
MounjaroTirzepatide27$30,685
Repatha SureclickEvolocumab38$26,536
FarxigaDapagliflozin Propanediol21$20,554
Spiriva RespimatTiotropium Bromide11$12,082
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$11,008
JanuviaSitagliptin Phosphate11$10,608
Atorvastatin Calcium277$2,609
Gabapentin117$2,527
Testosterone11$2,451
Albuterol Sulfate HfaAlbuterol Sulfate53$2,266

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$422$55,24150 claims
PfizerEliquis$82$47,68439 claims
Johnson & JohnsonXarelto$81$35,85025 claims
Astellas Pharma US IncMyrbetriq$266$35,75256 claims
Lilly USA, LLCMounjaro$237$30,68527 claims
AstraZenecaFarxiga$55$20,55421 claims
MerckJanuvia$29$10,60811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →